en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
4/2014
vol. 52
 
Share:
Share:
more
 
 
abstract:
Review paper

Pharmacological therapy of osteoporosis with bisphosphonates – for whom, what kind, and for how long?

Ewa Marcinowska-Suchowierska
,
Magdalena Walicka

Reumatologia 2014; 52, 4: 238–246
Online publish date: 2014/09/12
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
For many years bisphosphonates (BS) have played an important role in the treatment of postmenopausal osteoporosis. Additionally, they have recently been used in men and induced osteoporosis by administering glucocorticoids and some other secondary osteoporosis. Designing pharmacologically equivalent BS substance administered orally once a week or once a month allowed to reduce side effects related to the digestive system. Availability of intravenous BS substance resulted in a more frequent occurrence of the acute phase reactions. Recently a relation has been noticed between the use of BS and the occurrence of complications including osteonecrosis of the jaw and atypical subtrochanteric fractures. In this article the authors present current knowledge regarding BS treatment in osteoporosis and some adverse effects related to its long-term use. This information will help to optimize the length of treatment with BS and to make a decision about potential discontinuation of BS treatment.
keywords:

osteoporosis, bisphosphonates, drug safety







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.